Tolvasca 30mg (Tolvaptan)
Description of Tolvasca 30mg (Tolvaptan 30mg)
Tolvasca 30mg (Tolvaptan 30mg) decrease the level of a hormone whichcontrols the balance of water and salt (sodium) in the body. Peak levels of this hormone can lead an imbalance which results in low sodium levels and fluid retention.
Tolvasca 30mg (Tolvaptan 30mg)isneeded to cure hyponatremia (low levels of sodium in your blood) in people with heart failure, and certain hormonal imbalances. Tolvasca 30mg (Tolvaptan 30mg)improves urine flow without causing the body to lose too much sodium as you urinate
INDICATIONS of Tolvasca 30mg (Tolvaptan 30mg)
Tolvasca 30mg (Tolvaptan 30mg) is used for the treatment of patients with hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Tolvasca 30mg (Tolvaptan 30mg) is also used for hypervolemic and euvolemic hyponatremia (sodium concentration <125 mmol l–1) with heart failure and cirrhosisin patients. In this US country use this medicine frequently.
MECHANISM OF ACTION of Tolvasca 30mg (Tolvaptan 30mg)
Hyponat – O is a selective and competitive arginine vasopressin receptor 2 antagonist. Vasopressin acts on the V2 receptors found in the walls of the vasculature and luminal membranes of renal collecting ducts. By stopping V2 receptors in the renal collecting ducts, aquaporins avoid entering themselves into the walls thus preventing water absorption. This action finally results in an rises in urine volume, reduce urine osmolality, and increase electrolyte-free water clearance to reduce intravascular volume and an increase serum sodium levels. Hyponat – O is especially useful for heart failure patients as they have higher serum levels of vasopressin.
ADME of Tolvasca 30mg (Tolvaptan 30mg)
Absorption: Time to peak plasma concentration of Tolvasca 30mg (Tolvaptan 30mg) is 2-4 hours
The absolute bioavailability is unknown.
Distribution: Volume of distribution in healthy subjects is 3L/kg.
The plasma protein bounding of Tolvasca 30mg (Tolvaptan 30mg) is 99%
Metabolism: Tolvasca 30mg (Tolvaptan 30mg) is metabolism occurs by CYP3A4 enzyme in the liver.
Elimination: less than 1% is eliminated in the urine (unchanged form) and viafaecal is very little amount of renal elimination.
In oral dose, half-life of Tolvasca 30mg (Tolvaptan 30mg) is 12 hours.
PRECAUTIONS of Tolvasca 30mg (Tolvaptan 30mg)
- Tolvasca 30mg (Tolvaptan 30mg)can develops serious and likely fatal liver injury; acute liver failure needed liver transplantation reported; discontinue if laboratory abnormalities or signs or symptoms of liver injury are apparent.
• The conditions like Hypernatremia, hypovolemia, and/or dehydration; provoke patient to drink whenever thirsty
• Risk of potassium level increased
• Tolvasca 30mg (Tolvaptan 30mg)produce Osmotic demyelination syndrome is a harm along with too-fast correction of hyponatremia
DRUG INTERACTION of Tolvasca 30mg (Tolvaptan 30mg)
* When Tolvaptan interaction with P-gp inhibitors will have reductions in the dose of Hyponat-O 15mg
* Concomitant use of rifampin and Tolvasca 30mg (Tolvaptan 30mg)decrease exposure to tolvaptan by 85%.
* Combination with moderate CYP3A4 inhibitors will increase in exposure of Hyponat-O 15mg.
* Combination of lovastatin, digoxin, furosemide, and hydrochlorothiazide has no clinically relevant impact on the exposure to Tolvasca 30mg (Tolvaptan 30mg)
* Tolvaptanco administration with strong CYP3A4 inhibitors like ketoconazole will have highest labelled dose would be normal to cause an even heavy increase in exposure.
CONTRAINDICATION of Tolvasca 30mg (Tolvaptan 30mg)
Tolvasca 30mg (Tolvaptan 30mg)is contraindicated with following condition as
Patients with autosomal dominant polycystic kidney disease because the drug causes severe and possible fatal liver injury.
Required in acutely raised serum sodium
Patients inability to sense
PREGNANCY OF Tolvasca 30mg (Tolvaptan 30mg)
Pregnancy category is C: There are no sufficient and well tolerated studies of Tolvasca 30mg (Tolvaptan 30mg)tablets but can be used during pregnancy only if the possible benefits prove the possible risk to the fetus.
LACTATION OF Tolvasca 30mg (Tolvaptan 30mg)
LACTATION Tolvasca 30mg (Tolvaptan 30mg) excreted in human milk is unknown because most of the drugs are excreted into human milk,
Due to possible for serious adverse reaction in nursing infants from Tolvasca 30mg (Tolvaptan 30mg) tablets,
Taking into consideration the Tolvasca 30mg (Tolvaptan 30mg) tablets attention to the mother, a decision should be taken to discontinue breastfed or Tolvasca 30mg (Tolvaptan 30mg) drug
DOSAGE of Tolvasca 30mg (Tolvaptan 30mg)
Initial: 15 mg PO qDay
Maintenance: May increase to 30 mg qDay after at least 24 hr to achieve the optimal serum sodium level; not to exceed 60 mg/day
Not to exceed 30 days of treatment
Polycystic Kidney Disease
Initial: 45 mg PO taken on waking and 15 mg taken 8 hr later (ie, 60 mg/day) Advice the patients to drink enough water to avoid thirst or dehydration
Administration of Natriseshould be without food
Grape juice should be avoided during therapy with Natrise
There is no essential antitoxin for Natriseintoxication. The signs and symptoms of an acute overdose can be expected to be those of extra pharmacologic effect: a increase in serum sodium concentration, polyuria, thirst, and dehydration/hypovolemia. Administrating monotherapy oral doses up to 480 mg and multiple doses up to 300 mg once in a day for 5 days have been well accepted in studies in healthy subjects
STORAGE of Tolvasca 30mg (Tolvaptan 30mg)
Store the Tolvasca 30mg (Tolvaptan 30mg) at 25℃ (77 ℉)
Keep away from the children’s reach.
Dispense only in original containers.
If the patient is missed, then take the tablet dose immediately before the next dose timing arrives or skip the missed dose and continue the regular schedule.
Avoid having of double dose at a time.
Consult the doctor for further details.
No reviews found